PAG
NBSE

Private Advisor Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Private Advisor Group’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3
Closed – – 3597
2020
Q2 		$0 Buy
+3
New +$502 ﹤0.01% 3946

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Private Advisor Group's NBSE Position: Q3 2020 in Review

Private Advisor Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2020, closing a stake of 3 shares.

Private Advisor Group first reported a position in NBSE in Q2 2020 and held it in 1 quarter. The position peaked at $0 in Q2 2020. 50 funds tracked by Wall St. Rank hold NBSE as of Q3 2020.

  • Private Advisor Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 3 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2020.
  • Private Advisor Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $0 in Q2 2020.
  • 50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.